F15.982: Other stimulant use, unspecified with stimulant-induced sleep disorder

F15.982, other stimulant use, unspecified with stimulant-induced sleep disorder, is listed as a covered diagnosis in 5 Medicare billing and coding articles that apply to 14 HCPCS Level II codes, including G0399 (Home sleep test (hst) with type iii portable monitor…), G0400 (Home sleep test (hst) with type iv portable monitor…), G0398 (Home sleep study test (hst) with type ii portable monitor…). The articles come from 4 Medicare contractors. A listed diagnosis supports medical necessity only; coverage still depends on the LCD's criteria and on documentation in the medical record.

HCPCS Level II codes with F15.982 as a covered diagnosis

CodeDescriptionMedicare coverageDMEPOS fee 2026 (state range)Articles listing it
G0399Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturationCarrier judgment—1
G0400Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channelsCarrier judgment—1
G0398Home sleep study test (hst) with type ii portable monitor, unattended; minimum of 7 channels: eeg, eog, emg, ecg/heart rate, airflow, respiratory effort and oxygen saturationCarrier judgment—1
G0480Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performedCarrier judgment—2
G0483Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performedCarrier judgment—2
G0482Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performedCarrier judgment—2
G0481Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performedCarrier judgment—2
G0659Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classesCarrier judgment—2
G0152Services performed by a qualified occupational therapist in the home health or hospice setting, each 15 minutesCarrier judgment—1
G0155Services of clinical social worker in home health or hospice settings, each 15 minutesCarrier judgment—1
G0156Services of home health/hospice aide in home health or hospice settings, each 15 minutesCarrier judgment—1
G0299Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutesCarrier judgment—1
G0300Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutesCarrier judgment—1
G0451Development testing, with interpretation and report, per standardized instrument formCarrier judgment—1

Medicare policy articles listing F15.982

A diagnosis listed as covered in a billing and coding article supports medical necessity for the article's codes; it does not guarantee payment. Coverage depends on the LCD's criteria, the contractor's jurisdiction and documentation in the medical record.

Other F15 diagnoses (Other stimulant related disorders)

Frequently asked questions

Does Medicare cover F15.982 (Other stimulant use, unspecified with stimulant-induced…)?

Medicare covers items and services, not diagnoses. 5 Medicare billing and coding articles list F15.982 as a covered diagnosis for 14 HCPCS Level II codes: the diagnosis can support medical necessity for those codes, but payment still depends on the LCD's coverage criteria and the medical record.

Which HCPCS codes can be billed with ICD-10 F15.982?

The Level II codes from the policies most specific to this diagnosis are G0399 (Home sleep test (hst) with type iii portable monitor…, 1 article); G0400 (Home sleep test (hst) with type iv portable monitor…, 1 article); G0398 (Home sleep study test (hst) with type ii portable monitor…, 1 article); G0480 (Drug test(s), definitive, utilizing (1) drug…, 2 articles); G0483 (Drug test(s), definitive, utilizing (1) drug…, 2 articles). Code choice depends on the item supplied; check each code's descriptor.

Which Medicare policy articles list F15.982?

A56923 (Billing and Coding: Outpatient Sleep Studies); A56756 (Billing and Coding: Home Health - Psychiatric Care); A56818 (Billing and Coding: Urine Drug Testing), and 2 more articles.

What is ICD-10-CM code F15.982?

F15.982 is the ICD-10-CM code for other stimulant use, unspecified with stimulant-induced sleep disorder, in category F15 (Other stimulant related disorders), chapter 5: Mental, behavioral and neurodevelopmental disorders.

Next steps

Sources: CMS Medicare Coverage Database billing and coding articles (covered ICD-10 code lists and HCPCS links); ICD-10-CM FY2026; CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule 2026 (non-rural state fees). Not billing or legal advice.

Chapter 5: Mental, behavioral and neurodevelopmental disorders · All diagnoses · HCPCS lookup